Company Update: SK pharmteco to Expand Capabilities with Acquisition of Controlling Interest in CBM | Learn More
Logo yposkesi
waves image

Podcast: Building with the patient in mind: Designing a state-of-the-art facility for viral vector manufacturing

The cell and gene therapy space poses a number of unique challenges when it comes to facility design. In this episode, Louis-Marie De Montgrand and Morad El Gueddari discuss the key considerations for designing an advanced therapy manufacturing facility that can meet the needs of future commercial demand.

Listen to the podcast to learn more about:

  • Challenges when it comes to designing a facility for the cell and gene therapy space;
  • Key considerations for designing an advanced therapy manufacturing facility that can meet the needs of future commercial demand;
  • How to learn from previous experience and previous constructions;
  • Designing and building a new facility is a great advancement, but what about the experts that will work within it? How to recruit and retain staff in this volative era.


Listen to the podcast

Do you prefer to read the transcrit of the podcast? Click on the link below to do so.

Read the transcript of the podcast

About the speakers:

Louis-Marie De Montgrand, Chief Operational Officer at Yposkesi

Louis-Marie de Montgrand joined Yposkesi as Chief Operational Officer in June 2022. With more than 25 years of experience in leading Operations in Biopharma Industries, Louis-Marie held several positions at major industrial & CDMO actors. He started his career working for Sanofi as an EIT Process Eng, followed by 10 years at GSK being Head of Production then Head of Technical Services. After that, Louis-Marie became CMO Operations Director at Novasep and VP Operations – Viral Vector Services for Europe at Thermofisher.

Morad El Gueddari

Morad El Gueddari, Chief Pharmacist and Head of Quality at Yposkesi

Morad El Gueddari joined Yposkesi as Head of Operations in 2018 and became the Chief Pharmacist and Head of Quality in June 2022. Morad has 15 years of bioproduction and cell and gene therapy experience gained in various managerial roles in quality and GMP manufacturing at European pharmaceutical companies, including LFB and CELLforCURE (now part of Novartis). Dr. El Gueddari holds a PharmD from the Limoges, France Pharmacy School.

Published by Cell & Gene Therapy Insights 2023; 9(9), 1153–1160
DOI: 10.18609/cgti.2023.153

Created by Yerokhoff Kostyiantine